奥拉帕利辅助多西他赛+奥沙利铂化疗方案对卵巢癌患者血清FOLR1、HK10水平及生存率的影响  

Effects of Olapali-Assisted Docetaxel+Oxaliplatin Chemotherapy on Serum FOLR1,HK10 Levels and Survival Rate in Patients with Ovarian Cancer

作　　者：卢秋阳 袁婷婷 潘学景 LU Qiu-yang;YUAN Ting-ting;PAN Xue-jing(Department of Gynecology and Obstetrics,Nanyang Central Hospital,Nanyang,Henan,473000,China)

机构地区：[1]南阳市中心医院妇产科,河南南阳473000

出　　处：《中国血液流变学杂志》2024年第4期592-595,619,共5页Chinese Journal of Hemorheology

摘　　要：目的分析奥拉帕利辅助多西他赛+奥沙利铂化疗方案对卵巢癌患者血清叶酸受体α(FOLR1)、人激肽释放酶-10(HK10)水平及生存率的影响。方法前瞻性选取2021年5月—2023年5月南阳市中心医院68例卵巢癌患者,随机分为对照组、观察组,各34例。对照组采用多西他赛+奥沙利铂化疗方案治疗,观察组采用奥拉帕利辅助多西他赛+奥沙利铂化疗方案治疗。比较两组临床疗效、血清FOLR1、HK10水平、卡氏评分(KPS)、不良反应及生存率。结果观察组客观缓解率(ORR)(64.71%)高于对照组(38.24%)(P<0.05);治疗后观察组FOLR1、HK10水平低于对照组(P<0.05);治疗后观察组KPS评分高于对照组(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05);观察组治疗后半年、1年生存率均高于对照组(P<0.05)。结论卵巢癌患者采用奥拉帕利辅助多西他赛+奥沙利铂化疗方案治疗可下调FOLR1、HK10表达,改善患者体能状态,提高患者生存率,疗效显著,且安全性高。Objective To analyze the effects of Olapali-assisted Docetaxel+Oxaliplatin chemotherapy regimen on serum folate receptor alpha(FOLR1)and human kallikrein-10(HK10)levels and survival rate of ovarian cancer patients.Methods 68 cases of ovarian cancer patients in Nanyang Central Hospital were prospectively selected from May 2021 to May 2023 and randomly divided into the control group and observation group,each with 34 cases.The control group was treated with Docetaxel+Oxaliplatin chemotherapy,and the observation group was treated with Olapali-assisted Docetaxel+Oxaliplatin chemotherapy.The clinical efficacy,serum FOLR1,HK10 levels,KPS score,adverse reactions and survival rate were compared between the two groups.Results The objective remission rate(ORR)in observation group(64.71%)was higher than that in control group(38.24%)(P<0.05).After treatment,FOLR1 and HK10 levels in observation group were lower than those in control group(P<0.05).After treatment,the KPS score of observation group was higher than that of control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).The survival rate of observation group was higher than that of control group(P<0.05).Conclusion The chemotherapy regimen of Olapali-assisted Docetaxel+Oxaliplatin in ovarian cancer patients can down-regulate the expression of FOLR1 and HK10,improve the physical status of patients,and improve the survival rate of patients,with significant efficacy and high safety.

关 键 词：卵巢癌 奥拉帕利 叶酸受体Α 人激肽释放酶-10 生存率 

分 类 号：R737.31[医药卫生—肿瘤] R730.53[医药卫生—临床医学]